Conmed (CNMD) Misses Q3 EPS by 6c, Lowers FY Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures gain as oil pulls back ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Leerink Partners Cuts Price Target as Conmed (CNMD) Reports 6c EPS Miss
October 22, 2015 8:53 AM EDTLeerink Partners reiterated an Outperform rating on CONMED (NASDAQ: CNMD), and cut the price target to $53.00 (from $60.00), following the company's 3Q15 earnings results. 3Q revenues of $169M were below consensus' $173M estimate. EPS of $0.38 was below $0.44 estimate.
Analyst Richard Newitter commented,... More



